| Blue Channel Therapy | |
|
5460 Ward Rd Ste 150 Arvada CO 80002-1828 | |
| (720) 295-7548 | |
| Not Available |
| Full Name | Blue Channel Therapy |
|---|---|
| Speciality | Social Worker |
| Location | 5460 Ward Rd Ste 150, Arvada, Colorado |
| Authorized Official Name and Position | Maia Longenecker (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 7202957548 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Blue Channel Therapy 5460 Ward Rd Ste 150 Arvada CO 80002-1828 Ph: (720) 295-7548 | Blue Channel Therapy 5460 Ward Rd Ste 150 Arvada CO 80002-1828 Ph: (720) 295-7548 |
| NPI Number | 1811587199 |
|---|---|
| Provider Enumeration Date | 01/21/2021 |
| Last Update Date | 06/12/2023 |
| Certification Date | 06/12/2023 |
| Medicare PECOS PAC ID | 0941653364 |
|---|---|
| Medicare Enrollment ID | O20240201000494 |
News Archive
Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announce the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50°C for over 2 months. The technology can also be applied to emerging influenza and other vaccines.
Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large.
Child restraint laws across many states have gaps that leave unprotected passengers highly vulnerable to vehicle-crash injuries, a study by New York University has found.
CTS Corporation today announced fourth quarter 2009 revenues of $133.9 million, 6% higher than third quarter 2009 revenues of $126.6 million. Fourth quarter 2009 net earnings were $4.1 million, or $0.12 per diluted share, including a discrete tax valuation allowance charge of $2.5 million (or $0.07 per diluted share). Excluding this charge, fourth quarter non-GAAP adjusted net earnings were $6.6 million, or $0.19 per diluted share, compared to third quarter 2009 net earnings of $4.5 million, or $0.13 per diluted share.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811587199 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Provider Name | Maia A Longenecker |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1497180129 PECOS PAC ID: 4981994795 Enrollment ID: I20160607002569 |
News Archive
Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announce the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50°C for over 2 months. The technology can also be applied to emerging influenza and other vaccines.
Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large.
Child restraint laws across many states have gaps that leave unprotected passengers highly vulnerable to vehicle-crash injuries, a study by New York University has found.
CTS Corporation today announced fourth quarter 2009 revenues of $133.9 million, 6% higher than third quarter 2009 revenues of $126.6 million. Fourth quarter 2009 net earnings were $4.1 million, or $0.12 per diluted share, including a discrete tax valuation allowance charge of $2.5 million (or $0.07 per diluted share). Excluding this charge, fourth quarter non-GAAP adjusted net earnings were $6.6 million, or $0.19 per diluted share, compared to third quarter 2009 net earnings of $4.5 million, or $0.13 per diluted share.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
› Verified 6 days ago
| Provider Name | Lynne Cole |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1205373065 PECOS PAC ID: 7618312869 Enrollment ID: I20240228001084 |
News Archive
Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announce the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50°C for over 2 months. The technology can also be applied to emerging influenza and other vaccines.
Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large.
Child restraint laws across many states have gaps that leave unprotected passengers highly vulnerable to vehicle-crash injuries, a study by New York University has found.
CTS Corporation today announced fourth quarter 2009 revenues of $133.9 million, 6% higher than third quarter 2009 revenues of $126.6 million. Fourth quarter 2009 net earnings were $4.1 million, or $0.12 per diluted share, including a discrete tax valuation allowance charge of $2.5 million (or $0.07 per diluted share). Excluding this charge, fourth quarter non-GAAP adjusted net earnings were $6.6 million, or $0.19 per diluted share, compared to third quarter 2009 net earnings of $4.5 million, or $0.13 per diluted share.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
› Verified 6 days ago
| Provider Name | Kathleen Marie Watson |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1942536040 PECOS PAC ID: 9032554183 Enrollment ID: I20240228001613 |
News Archive
Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announce the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50°C for over 2 months. The technology can also be applied to emerging influenza and other vaccines.
Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large.
Child restraint laws across many states have gaps that leave unprotected passengers highly vulnerable to vehicle-crash injuries, a study by New York University has found.
CTS Corporation today announced fourth quarter 2009 revenues of $133.9 million, 6% higher than third quarter 2009 revenues of $126.6 million. Fourth quarter 2009 net earnings were $4.1 million, or $0.12 per diluted share, including a discrete tax valuation allowance charge of $2.5 million (or $0.07 per diluted share). Excluding this charge, fourth quarter non-GAAP adjusted net earnings were $6.6 million, or $0.19 per diluted share, compared to third quarter 2009 net earnings of $4.5 million, or $0.13 per diluted share.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
› Verified 6 days ago
News Archive
Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announce the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50°C for over 2 months. The technology can also be applied to emerging influenza and other vaccines.
Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large.
Child restraint laws across many states have gaps that leave unprotected passengers highly vulnerable to vehicle-crash injuries, a study by New York University has found.
CTS Corporation today announced fourth quarter 2009 revenues of $133.9 million, 6% higher than third quarter 2009 revenues of $126.6 million. Fourth quarter 2009 net earnings were $4.1 million, or $0.12 per diluted share, including a discrete tax valuation allowance charge of $2.5 million (or $0.07 per diluted share). Excluding this charge, fourth quarter non-GAAP adjusted net earnings were $6.6 million, or $0.19 per diluted share, compared to third quarter 2009 net earnings of $4.5 million, or $0.13 per diluted share.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
› Verified 6 days ago
Towne Square Associates, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5738 Olde Wadsworth Blvd, Arvada, CO 80002 Phone: 303-420-9565 Fax: 303-456-9284 | |
Transition Counseling, Pc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 9989 W 60th Ave Ste 250, Arvada, CO 80004 Phone: 303-550-0172 Fax: 303-431-1880 | |
Rising Star Behavior Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5921 Taft St, Arvada, CO 80004 Phone: 720-375-4949 | |
Intuitive Life Wellness Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 8344 Holman St Unit B, Arvada, CO 80005 Phone: 309-267-2534 | |
A Good Nights Sleep Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 8241 W Pomona Dr, Arvada, CO 80005 Phone: 720-414-0242 | |
Above And Beyond Enterprises Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6432 West 78th Ave., Arvada, CO 80003 Phone: 720-495-7692 | |
Stephanie Camins Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7985 Vance Dr Ste 106b, Arvada, CO 80003 Phone: 303-380-5526 Fax: 303-432-2632 |